BioSpace News Archive

- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif.--( BUSINESS WIRE )-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinica

Sept. 16, 2020 11:45 UTC -- First-In-Human Trial Targeting the Immune Inhibitory Receptor, LILRB4 -- -- Preclinical Data Show LILRB4 Plays a Role in Immune Suppression and Tumor Infiltration -- PALO ALTO, Calif.--( BUSINESS WIRE )-- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a cancer immunotherapy company focused on developing first-in-class biotherapeutics that target novel immunosuppressive myeloid checkpoints, announced today that the first patient has been dos

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it is participating in the virtual, inaugural Sepsis Alliance Summit taking place September 16-17, 2020, through a sponsorship and virtual booth in honor of Sepsis Awareness Month (September).

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Ling Zeng as chief legal officer and secretary and a member of the Company’s executive leadership team, e

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today provided a corporate update.

Synaffix B.V., a biotechnology company enabling antibody-drug conjugates with best-in-class therapeutic index, based on proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technology platforms, announces promising findings from its latest in vivo benchmarking study.

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has filed an Emergency Use Authorization (EUA) application with the Food and Drug Administration (FDA) for measuring COVID-19 neutralizing antibodies in plasma and serum through its first-in-class rapid diagnostic test.

EVERSANA™, the leading provider of global commercial services to the life sciences industry, today launched ACTICS by EVERSANA™, the technology-enabled solution to optimize end-to-end commercial success for life science companies

AllianceRx Walgreens Prime leader recognized for furthering specialty pharmacy education, helped develop NASP’s certified specialty pharmacist (CSP) accreditation program

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system’s antimicrobial susceptibility testing (AST) menu for bloodstream infections.